

Referral Support Service

Dermatology

D21 Alopecia

Definition

Alopecia = hair loss

General Points

Alopecia areata (AA): round bald patches that appear suddenly, it is an auto-immune form of hair loss and may be associated with other autoimmune disorders, there is a positive FH in 1 in 12.

Children with alopecia areata tend to do less well than adults.

Prognosis is worse with:

- Early age of onset
- Increased extent of areas affected
- Occipital pattern of loss
- Associated nail dystrophy.

70% regrow within 12 months. Regrowth may be initially white/grey but the pigment usually returns later.

Management

Encourage smoking cessation

Encourage weight loss (if appropriate)

Check TFTs (ferritin and zinc levels not needed for alopecia areata but check ferritin with more generalised hair loss and aim for a level of at least 60).

For more profuse hair loss, check medication: stopping contraceptive pill can cause hair loss (but the hair would have been gradually lost without the pill anyway); statins. Medication can often be implicated-

Medication known to cause alopecia include*:

Amfetamines	Hypolipidaemics
Anticoagulants (warfarin, heparin, heparinoids)	Interferons

Responsible GP: Dr Alison Hunter

Responsible Consultant: Dr Julia Stainforth

Responsible Pharmacist: Laura Angus

©NHS Vale of York Clinical Commissioning Group – Version 2

The on-line version is the only version that is maintained. Any printed copies should, therefore, be viewed as 'uncontrolled' and as such may not necessarily contain the latest updates and amendments.

Clinical Research & Effectiveness approved: May 2016

Date published: Aug 2016

Next Review: Aug 2018

Antidepressants	Leflunomide
Antithyroid drugs	Lithium
Beta-blockers	Oral contraceptives
Carbamazepine	Phenytoin
Cimetidine	Retinoids
Cytotoxic agents	Tamoxifen
	Valproate

*Please note this list is not exhaustive

See BNF for more information and include details of medication in referral letter, including any treatments stopped in the last 4 months. If you think a medication may be causing hair loss please email rdtc.rxsupp@nuth.nhs.uk for advice.

Skin scrapings for fungal infection if flaking is present.

Outcome

Treatment options:

- **If there is evidence of hair regrowth** (short, fine, tapered hair or white hair), there is no need for treatment.
- **If there is no hair regrowth and the person has less than 50% hair loss**, discuss the option of watching and waiting, with no treatment.
- **If there is no hair regrowth and the person has more than 50% hair loss, or treatment is preferred:**
 - Refer to a dermatologist.
 - If the person has less than 50% hair loss, there is better evidence to support the use of intralesional corticosteroids than other treatments.
 - If the person has more than 50% hair loss, there is better evidence to support the use of topical immunotherapy than other treatments, although its availability may be limited.
 - For more information on these and other treatments, see Specialist treatments.
 - If the diagnosis is certain, for an adult who is not pregnant and is waiting to see a specialist or declines referral:
 - Consider a trial of a potent topical corticosteroid (such as **betamethasone valerate 0.1%** (as Betnovate®*), **fluocinolone acetonide 0.025%** (as Synalar®* 0.025% cream)) or very potent topical corticosteroids (such as **clobetasol propionate 0.05%** scalp application (as

Responsible GP: Dr Alison Hunter
Responsible Consultant: Dr Julia Stainforth
Responsible Pharmacist: Laura Angus

Clinical Research & Effectiveness approved: May 2016
Date published: Aug 2016
Next Review: Aug 2018

©NHS Vale of York Clinical Commissioning Group – Version 2

The on-line version is the only version that is maintained. Any printed copies should, therefore, be viewed as 'uncontrolled' and as such may not necessarily contain the latest updates and amendments.

Dermovate®* scalp)) for 3 months (off-label use). *topical steroids should be prescribed by brand name.

- Do not use on the face (such as on the beard or eyebrows).
- For children and pregnant or breastfeeding women, discuss with a dermatologist before starting interim treatment.

Treatment options for alopecia areata which might be used by a specialist, but are not recommended for use in primary care, include:

- Intralesional corticosteroids (available on the NHS and used by local Consultant Dermatologists)
- Topical immunotherapy (available on the NHS and used by local Consultant Dermatologists)
- Topical minoxidil (Only available privately. Not available on the NHS)
- Topical dithranol (now rarely used).
- Topical or systemic psoralen plus ultraviolet A light therapy (PUVA) (available on the NHS)
- Oral ciclosporin (available on the NHS)
- Dermatography (tattooing) (Only available privately. Not available on the NHS)
- Wigs (available on the NHS and used by local Consultant Dermatologists).

Alopecia totalis (where all the hair on the scalp is lost) and **universalis** (where all body hair is lost)- only a very small proportion recover.

Telogen effluvium: an increase in the number of hairs shed with associated thinning of the hair; usually occurs 2-3 months after an event such as childbirth, serious illness, fever, operation, accident or other form of stress. Recovery occurs over 6-9 months but may be incomplete.

Traction alopecia: an acquired form of hair loss due to prolonged or repeated tension on the hair e.g. with tight braiding, tight ponytails etc. Usually affects frontal and temporal areas but depends on hair-style. Can be temporary or permanent.

Female pattern hair loss (androgenetic alopecia)

40% of women by the age of 50 show evidence of hair loss; usually presents as hair thinning over the vertex rather than a bald patch and hair won't grow as long as previously; there is a strong genetic component which can be inherited from either parent

Consider causes such as PCOS, congenital adrenal hyperplasia or androgen producing tumours if there are other signs of virilisation.

Check TFT, ferritin (aim for 60+). Check LH/FSH/testosterone only if indicated.

Assess psychological impact.

- Doing nothing may be the best option in many women.

Responsible GP: Dr Alison Hunter
Responsible Consultant: Dr Julia Stainforth
Responsible Pharmacist: Laura Angus

Clinical Research & Effectiveness approved: May 2016

Date published: Aug 2016

Next Review: Aug 2018

©NHS Vale of York Clinical Commissioning Group – Version 2

The on-line version is the only version that is maintained. Any printed copies should, therefore, be viewed as 'uncontrolled' and as such may not necessarily contain the latest updates and amendments.

- **Using a medical treatment.**
 - **Topical minoxidil 2% (Regaine®)** is the only drug licensed for use in female androgenetic alopecia (5% is unlicensed but may be used)
 - It is **NOT prescribable on the NHS** but can be bought over the counter or prescribed privately.
 - To gain and maintain benefit, twice-daily application must continue indefinitely - cessation of treatment will lead to loss of all results within 4 months.

Do not offer other medications -

- Finasteride is contraindicated in women.

Co-cyprindiol or **spironolactone 50-100mg** may help-if suitable for these, assess response over 6-12months. See BNF for additional prescribing advice.

Androgenetic alopecia male (male pattern baldness)

Options for private treatment include **minoxidil 5%** and **finasteride 1mg** tablets but these are not available on the NHS.

Referral Information

Indications for referral

Scarring alopecia

Information to include in referral letter

Appearance of the scalp

Tests undertaken

Site(s) affected and size of areas(s)

Length of time alopecia has affected the patient and the emotional impact

Any treatments tried

Investigations prior to referral

Detailed above

Referral Criteria

Provide patient with PIL –see below

Patient information leaflets/ PDAs

<http://www.patient.co.uk/search.asp?searchterm=alopecia&searchcoll=All&x=0&y=0>

References

Responsible GP: Dr Alison Hunter

Responsible Consultant: Dr Julia Stainforth

Responsible Pharmacist: Laura Angus

©NHS Vale of York Clinical Commissioning Group – Version 2

The on-line version is the only version that is maintained. Any printed copies should, therefore, be viewed as 'uncontrolled' and as such may not necessarily contain the latest updates and amendments.

Clinical Research & Effectiveness approved: May 2016

Date published: Aug 2016

Next Review: Aug 2018

<http://www.dermnetnz.org/topics/hair-and-scalp>

[NICE CKS Alopecia-areata](#) (May 2014)

[NICE CKS Alopecia androgenetic - female](#) (Jan 2012)

Responsible GP: Dr Alison Hunter
Responsible Consultant: Dr Julia Stainforth
Responsible Pharmacist: Laura Angus

Clinical Research & Effectiveness approved: May 2016

Date published: Aug 2016

Next Review: Aug 2018

©NHS Vale of York Clinical Commissioning Group – Version 2

The on-line version is the only version that is maintained. Any printed copies should, therefore, be viewed as 'uncontrolled' and as such may not necessarily contain the latest updates and amendments.